Ovid Therapeutics Inc. (OVID): R&D Expense
$25.58M
Year ended 2025-12-31
$33.60M
Trailing 12 months to 2026-06-30
+1.3%
3-year compound annual growth
-16.6%
5-year compound annual growth
+14.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.58M | -30.4% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $36.77M | +28.6% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $28.59M | +16.1% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $24.62M | -47.6% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $46.94M | -26.0% | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | $63.42M | +50.4% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $42.16M | +24.8% | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | $33.79M | -32.4% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $49.97M | +421.3% | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | $9.59M | +45.0% | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | $6.61M | n/a | 2018-03-29, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $300.94M | +43.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $177.29M | +36.9% |
| Adagene Inc. (ADAG) | 2025-12-31 | $22.03M | -23.4% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $28.53M | -50.4% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $52.65M | +56.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $16.73M | +41.0% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $65.58M | +3.0% |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗